Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
Status:
Completed
Trial end date:
2018-05-21
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can
find cancer cells and carry tumor-killing substances to them without harming normal cells.
Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to
kill cancer cells or stop them from growing. Giving radiolabeled monoclonal antibodies
together with etoposide and cyclophosphamide before a peripheral blood stem cell transplant
may be an effective treatment for non-Hodgkin lymphoma.
PURPOSE: This phase I/II trial is studying the side effects and best dose of yttrium Y 90
ibritumomab tiuxetan when given together with etoposide and cyclophosphamide followed by an
autologous stem cell transplant and to see how well it works in treating patients with
non-Hodgkin lymphoma.